Bristol-Myers Squibb Co (NYSE:BMY) crossed MACD Bullish signal line on Friday, June 26, 2020

Business or finance concept : Asia Pacific stock market data and candle stick graph chart on monitor

Bullish Bristol-Myers Squibb Co NYSE:BMY Grade : F stock signal line crossed on Friday, June 26, 2020. on Thursday 11th June’s trading session, with a change of 0.73% per share while daily volume of 15,265,600 changed hands which is surge of 0.94%

Bristol-Myers Squibb Co NYSE:BMY Grade : F stock BMY closed up 0.73 percent on Thursday, June 25, 2020, on approximately normal volume.

Earning Bristol-Myers Squibb Co NYSE:BMY

Bristol-Myers Squibb last issued its quarterly earnings results on May 7th, 2020. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.23. The company earned $10.78 billion during the quarter, compared to analyst estimates of $10.04 billion. Its revenue was up 82.1% on a year-over-year basis. Bristol-Myers Squibb has generated $4.69 earnings per share over the last year and currently has a price-to-earnings ratio of 71.8. Bristol-Myers Squibb has confirmed that its next quarterly earnings report will be published on Thursday, August 6th, 2020. Bristol-Myers Squibb will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

About Bristol-Myers Squibb Co NYSE:BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Grade : F